• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy.

作者信息

Hasan Shemonti, Zorio Onilia, Keegan B Mark, Weinshenker Brian G, Flanagan Eoin P, Tobin W Oliver, Kantarci Orhun H, Toledano Michel, Pittock Sean J, Lopez-Chiriboga Sebastian, Zekeridou Anastasia, Valencia-Sanchez Cristina

机构信息

Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA.

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

出版信息

J Neurol. 2023 Oct;270(10):4707-4712. doi: 10.1007/s00415-023-11933-6. Epub 2023 Aug 19.

DOI:10.1007/s00415-023-11933-6
PMID:37597071
Abstract
摘要

相似文献

1
Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy.免疫检查点抑制剂癌症免疫治疗后脱髓鞘疾病活动的频率
J Neurol. 2023 Oct;270(10):4707-4712. doi: 10.1007/s00415-023-11933-6. Epub 2023 Aug 19.
2
Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.免疫检查点抑制剂相关性肺炎的临床诊断与治疗。
Thorac Cancer. 2020 Jan;11(1):191-197. doi: 10.1111/1759-7714.13240. Epub 2019 Nov 24.
3
Sex - a potential factor affecting immune checkpoint inhibitor therapy for cancers.性别——影响癌症免疫检查点抑制剂治疗的一个潜在因素。
Front Immunol. 2022 Oct 18;13:1024112. doi: 10.3389/fimmu.2022.1024112. eCollection 2022.
4
[Encephalitis associated to immune checkpoint inhibitors].[与免疫检查点抑制剂相关的脑炎]
Medicina (B Aires). 2023;83(3):471-474.
5
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.免疫检查点抑制剂的眼部不良反应：梅奥诊所的经验。
Br J Ophthalmol. 2021 Sep;105(9):1263-1271. doi: 10.1136/bjophthalmol-2020-316970. Epub 2020 Aug 23.
6
Management of immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关皮肤不良反应的管理。
Thorac Cancer. 2020 Feb;11(2):488-492. doi: 10.1111/1759-7714.13275. Epub 2019 Dec 9.
7
Why are immune adverse events so common with checkpoint inhibitor therapy?为什么免疫相关不良事件在检查点抑制剂治疗中如此常见？
Ann Allergy Asthma Immunol. 2021 Jun;126(6):608-610. doi: 10.1016/j.anai.2021.03.016. Epub 2021 Mar 25.
8
Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management.肾上腺功能不全：免疫检查点抑制剂和免疫相关不良事件管理。
Clin J Oncol Nurs. 2020 Jun 1;24(3):240-243. doi: 10.1188/20.CJON.240-243.
9
[Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].[恶性肿瘤中检查点抑制剂诱导的免疫相关不良事件的预测生物标志物]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020 Dec 30;42(6):825-830. doi: 10.3881/j.issn.1000-503X.11534.
10
Hyperprogressive disease in patients receiving immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的患者中的超进展性疾病。
Curr Probl Cancer. 2021 Jun;45(3):100688. doi: 10.1016/j.currproblcancer.2020.100688. Epub 2020 Dec 9.

引用本文的文献

1
Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L).多发性硬化症的治疗进展：新型疗法（免疫检查点抑制剂、嵌合抗原受体T细胞疗法、抗CD40L）
Neurotherapeutics. 2025 Jul;22(4):e00558. doi: 10.1016/j.neurot.2025.e00558. Epub 2025 Feb 27.
2
Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的多发性硬化症患者的炎症性疾病。
Ann Clin Transl Neurol. 2025 Mar;12(3):643-647. doi: 10.1002/acn3.52287. Epub 2024 Dec 31.

本文引用的文献

1
Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.富马酸二甲酯延缓放射性孤立综合征中的多发性硬化进展。
Ann Neurol. 2023 Mar;93(3):604-614. doi: 10.1002/ana.26555. Epub 2022 Dec 10.
2
Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的多发性硬化症患者的神经疾病活动情况。
Mult Scler. 2023 Mar;29(3):471-474. doi: 10.1177/13524585221117949. Epub 2022 Aug 11.
3
Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report.
非小细胞肺癌和多发性硬化症患者免疫检查点治疗引发的颅内并发症：病例报告
JTO Clin Res Rep. 2021 May 18;2(6):100183. doi: 10.1016/j.jtocrr.2021.100183. eCollection 2021 Jun.
4
Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature.与免疫检查点抑制剂相关的中枢神经系统脱髓鞘：文献综述
Front Neurol. 2020 Dec 11;11:538695. doi: 10.3389/fneur.2020.538695. eCollection 2020.
5
Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.神经自身免疫与免疫检查点抑制剂：自身抗体谱与结局。
Neurology. 2020 Oct 27;95(17):e2442-e2452. doi: 10.1212/WNL.0000000000010632. Epub 2020 Aug 13.
6
Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event.孤立综合征的放射学研究：10 年临床事件风险预测。
Ann Neurol. 2020 Aug;88(2):407-417. doi: 10.1002/ana.25799. Epub 2020 Jun 29.
7
Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.一名非小细胞肺癌患者使用帕博利珠单抗后出现多发性硬化症。
J Neurol. 2019 Dec;266(12):3163-3166. doi: 10.1007/s00415-019-09562-z. Epub 2019 Oct 4.
8
Multiple sclerosis outcomes after cancer immunotherapy.癌症免疫疗法治疗多发性硬化症的结果。
Clin Transl Oncol. 2019 Oct;21(10):1336-1342. doi: 10.1007/s12094-019-02060-8. Epub 2019 Feb 20.
9
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.与免疫检查点抑制剂相关的神经不良事件：文献复习。
Eur J Cancer. 2017 Mar;73:1-8. doi: 10.1016/j.ejca.2016.12.001. Epub 2017 Jan 5.
10
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.CTLA4作为多发性硬化症发展中的免疫检查点
Ann Neurol. 2016 Aug;80(2):294-300. doi: 10.1002/ana.24715. Epub 2016 Jul 15.